Pliant Therapeutics (PLRX) News Today $13.37 +0.06 (+0.45%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 2:40 AM | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 18, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by Needham & Company LLCJuly 17, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Given Buy Rating at HC WainwrightJuly 16, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research report on Tuesday.July 13, 2024 | insidertrades.comPliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 7,656 SharesJuly 13, 2024 | insidertrades.comKeith Lamont Cummings Sells 10,911 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) StockJuly 11, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Trading Up 8.7%Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 8.7%July 5, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.29Pliant Therapeutics (NASDAQ:PLRX) Hits New 52-Week Low at $10.29July 1, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from BrokeragesPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has earned a consensus recommendation of "Buy" from the nine analysts that are covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that haveJune 27, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Reaches New 1-Year Low at $10.36Pliant Therapeutics (NASDAQ:PLRX) Hits New 12-Month Low at $10.36June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 21, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Shares Up 3.2%Pliant Therapeutics (NASDAQ:PLRX) Trading 3.2% HigherJune 19, 2024 | marketbeat.comMass General Brigham Inc Makes New Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Mass General Brigham Inc bought a new position in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 288,690 shares of the company's stock, valuJune 18, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Reaches New 12-Month Low at $10.56Pliant Therapeutics (NASDAQ:PLRX) Sets New 52-Week Low at $10.56June 17, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Trading Down 5.3%Pliant Therapeutics (NASDAQ:PLRX) Trading Down 5.3%June 13, 2024 | globenewswire.comPliant Therapeutics Announces Appointment of Steve Krognes to Board of DirectorsJune 13, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Shares Up 4.3%Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 4.3%June 13, 2024 | marketbeat.comGreat Point Partners LLC Has $33.02 Million Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Great Point Partners LLC increased its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,823,184 shares of the company's stock after purcJune 12, 2024 | globenewswire.comPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 12, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Stake Boosted by First Light Asset Management LLCFirst Light Asset Management LLC increased its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 22.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 3,591,776 shares of the company's stock after buying an additional 658,516 shares duringJune 7, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Reaches New 52-Week Low at $11.21Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year Low at $11.21June 7, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX)HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Pliant Therapeutics in a report on Friday.June 7, 2024 | marketbeat.comUBS Group AG Purchases 71,369 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)UBS Group AG boosted its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 26.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 342,173 shares of the company's stock after purchasing anJune 6, 2024 | globenewswire.comPliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™June 6, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Recommendation of "Buy" by BrokeragesPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has been given an average rating of "Buy" by the nine research firms that are covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month target price amJune 4, 2024 | marketbeat.comRhenman & Partners Asset Management AB Sells 217,894 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Rhenman & Partners Asset Management AB cut its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 65.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,741 shares of the company'June 4, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading VolumePliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading VolumeMay 27, 2024 | marketbeat.comFranklin Resources Inc. Acquires 62,173 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Franklin Resources Inc. boosted its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 4.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,579,572 shares of the company's stock after purchasing anMay 24, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Stock Price Down 4.5%Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 4.5%May 21, 2024 | globenewswire.comPliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics on Promising Bexotegrast Trial Results in IPFMay 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)May 15, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Trading Up 5.5%Pliant Therapeutics (NASDAQ:PLRX) Shares Up 5.5%May 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Tenet Healthcare (THC)May 14, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $13.67Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $13.67May 14, 2024 | msn.comPliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In PatientsMay 14, 2024 | globenewswire.comPliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisMay 10, 2024 | marketbeat.comHC Wainwright Comments on Pliant Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:PLRX)Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - HC Wainwright decreased their Q2 2024 earnings per share estimates for Pliant Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.82) per share for the qMay 8, 2024 | markets.businessinsider.comPliant Therapeutics: Advancing Trials and Diversifying Pipeline Justify Buy RatingMay 8, 2024 | markets.businessinsider.comBuy Rating for Pliant Therapeutics: Promising Trials and Strategic Shifts Signal Growth PotentialMay 8, 2024 | finance.yahoo.comPliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)May 7, 2024 | markets.businessinsider.comBullish Outlook: Buy Rating on Pliant Therapeutics Amid Strong Clinical Trials and Solid FinancialsMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Pliant Therapeutics’ Promising Pipeline and Financial PrudenceMay 7, 2024 | msn.comThese Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 EarningsMay 7, 2024 | marketbeat.comCitigroup Trims Pliant Therapeutics (NASDAQ:PLRX) Target Price to $44.00Citigroup cut their price objective on Pliant Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday.May 7, 2024 | tmcnet.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 7, 2024 | finance.yahoo.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 7, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) PT Raised to $48.00 at OppenheimerOppenheimer raised their price target on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday.May 7, 2024 | marketbeat.comPliant Therapeutics' (PLRX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Pliant Therapeutics in a research report on Tuesday.May 6, 2024 | investorplace.comPLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024 Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Rare signal predicts 50% market drop - before election (Ad)The market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors. Take these 4 steps to protect your retirement here. PLRX Media Mentions By Week PLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRX News Sentiment▼1.610.62▲Average Medical News Sentiment PLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRX Articles This Week▼22▲PLRX Articles Average Week Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANNX News FGEN News HCM News XENE News IDYA News FOLD News MLTX News ACAD News GERN News MORF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.